Intas Pharmaceuticals Limited Mitoxantrone Export Data — India (DGFT 2022–2026)

Name: Intas Pharmaceuticals Limited Mitoxantrone Export Records India — #2 Exporter, 13 Shipments, $650.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus
Published: 2026-05-01T00:00:00Z
License: https://transdatanexus.com/terms-and-conditions

Suresh Sormare

Mitoxantrone

India Pharmaceutical Trade Intelligence

$1.9M42 Suppliers35 CountriesHS 30049049

ExportsIndia → NAMIBIA47.0%India → MEXICO31.0%

Intas Pharmaceuticals Limited — Mitoxantrone Exporter #2 | $650.0K Trade Value | TransData Nexus | TransData Nexus

Intas Pharmaceuticals Limited — Mitoxantrone Exporter Profile

Indian Pharmaceutical Exporter · #2 for Mitoxantrone · $650.0K export value · DGFT Verified

Intas Pharmaceuticals Limited is the #2 Indian exporter of Mitoxantrone with $650.0K in export value and 13 verified shipments. Intas Pharmaceuticals Limited holds a 34.4% market share in Mitoxantrone exports across 4 countries. The company exports 75 pharmaceutical products worth $372.3M across 19 therapeutic categories.

Intas Pharmaceuticals Limited — Mitoxantrone Export Profile: Buyers & Destinations

Intas Pharmaceuticals Limited Mitoxantrone export treemap — buyers and destination countries | TransData Nexus

Where Does Intas Pharmaceuticals Limited Export Mitoxantrone?

Country	Value	Shipments	Share
MEXICO	$150.0K	3	56.4%
NETHERLANDS	$72.5K	4	27.2%
FRANCE	$41.2K	2	15.5%
MALTA	$2.4K	4	0.9%

Who Are the Top Buyers of Mitoxantrone from Intas Pharmaceuticals Limited?

Buyer	Country	Value	Orders
ACCORD FARMA S.A.DE C.V	MEXICO	$100.0K	2
ALLOGA FRANCE	FRANCE	$94.2K	5
TO THE ORDER.	MEXICO	$50.0K	1
SITE D#AMIENS	FRANCE	$19.6K	1
TO THE ORDER	MALTA	$1.4K	2
PHARMADOX HEALTHCARE LIMITED	MALTA	$985	2

Intas Pharmaceuticals Limited supplies Mitoxantrone to 6 buyers globally. The largest buyer is ACCORD FARMA S.A.DE C.V (MEXICO), followed by ALLOGA FRANCE (FRANCE) and TO THE ORDER. (MEXICO). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.

What Mitoxantrone Formulations Does Intas Pharmaceuticals Limited Export?

Product Description / Formulation	Value	Shipments
PH.DRU.&MED: BRESNIX MITOXANT 20MG/10ML 1X1V ACC MEX Each mL contains: Mitoxantrone hydroc. Ph. Eur equ.to Mitoxant. 2mg	$50.0K	1
PHARMA.DRUGS & MEDICINE BRESNIX MITOXANT20MG/10ML 1X1V ACC MEX EACH ML CONT.MITOXANTRONE HYDROCHLORIDE PH.EUR.EQUIVALEN	$50.0K	1
PHARMA.DRUGS & MEDICINE BRESNIX MITOXANT20MG/10ML 1X1V ACC MEX EACH ML CONTS.MITOXANTRONE HYDROCHLORIDE PH.EUR.EQUIVALE	$50.0K	1
PHA.DRU & MEDI MITOXANTRONE2MG/ML5MLX1V(ACCORD-FRANCE EACH ML CONTAINS : MITOXANTRONE HYDROCHLORIDE PH.EUR. EQ. TO MINOS	$41.2K	2
PHARMA DRUGS & MEDI MITOXANTRONE,2MG/ML,5MLx1V(ACCORD-FRANCE AS PER INVOICE	$37.6K	2
PHARMA DRUGS MEDI MITOXANTRONE 2MG ML 5MLx1V ACCORD FRANCE AS PER INVOICE	$34.9K	2
PHARMA DRUGS & MEDI: MITOXANTRONE,2MG/ML,5MLx1V (ACCORD-FRANCE 26X1X1VIAL	$710	1
PHARMA DRUGS & MEDI: MITOXANTRONE,2MG/ML,5MLx1V(ACCORD-FRANCE 26X1X1VIAL	$673	1
PHARMA DRUGS & MEDI: MITOXANTRONE2MG/ML5MLX1V(ACCORD-FRANCE 26X1X1VIALNOS	$498	1
PHARMA DRUGS & MEDI: MITOXANTRONE2MG/ML5MLX1V (ACCORD-FRANCE 26X1X1VIALNOS	$486	1

Intas Pharmaceuticals Limited exports 10 distinct Mitoxantrone formulations including tablets, capsules, syrups, and combination drugs. The top formulation is PH.DRU.&MED: BRESNIX MITOXANT 20MG/10ML 1X1V ACC MEX Each mL with 1 shipments worth $50.0K.

How Does Intas Pharmaceuticals Limited Compare to Nearest Mitoxantrone Exporters?

Exporters ranked immediately above and below #2 by export value

#	Supplier	Export Value	Shipments	Countries	Avg/Shipment
2	INTAS PHARMACEUTICALS LIMITED ★	$650.0K	13	4	$50.0K
1	MVL GLOBAL	$150.0K	3	1	$50.0K
3	MEDWISE OVERSEAS PRIVATE LIMITED	$76.3K	3	1	$25.4K

Intas Pharmaceuticals Limited ranks #2 among 42 Indian Mitoxantrone exporters. Average shipment value of $50.0K compared to the market average of $22.5K. The closest competitors by value are MVL GLOBAL and MEDWISE OVERSEAS PRIVATE LIMITED.

Which Indian Ports Ship Mitoxantrone Exports?

Port	Shipments	% Share
SAHAR AIR CARGO ACC (INBOM4)	28	25.5%
SAHAR AIR	28	25.5%
DELHI AIR CARGO ACC (INDEL4)	14	12.7%
Bombay Air	7	6.4%
DELHI AIR	4	3.6%
AHEMDABAD AIR	3	2.7%
COCHIN AIR	3	2.7%
Bombay Air Cargo	3	2.7%

Geopolitical & Trade Policy Impact on Intas Pharmaceuticals Limited's Mitoxantrone Exports

The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Intas Pharmaceuticals. The Israel-Iran tensions have led to increased security risks in the Strait of Hormuz and the Red Sea–Suez Canal corridor, prompting major carriers to reroute shipments around the Cape of Good Hope. This detour has extended transit times by 10–20 days and raised freight rates by 40–50% on key India–Europe routes, impacting the cost-effectiveness and timeliness of exports. (livemint.com)

Conversely, the ongoing US-China trade tensions have opened avenues for Indian pharmaceutical companies to capture a larger share of the U.S. market. Intas's acquisition of UDENYCA® and the FDA's acceptance of its biosimilar applications position the company to leverage these opportunities effectively. However, compliance with the European Union's Falsified Medicines Directive (FMD) remains a critical factor for market access. Intas's proactive approach in securing partnerships and ensuring regulatory compliance underscores its commitment to maintaining and expanding its presence in the European market.

Intas Pharmaceuticals Limited — Regulatory Compliance & Quality Standards

Maintaining stringent regulatory compliance is paramount for Indian pharmaceutical exporters. Intas Pharmaceuticals has demonstrated a strong commitment to adhering to international quality standards, as evidenced by its successful acquisitions and partnerships that necessitate compliance with FDA, WHO, and EU Good Manufacturing Practices (GMP). The company's proactive engagement in regulatory processes, such as the FDA's acceptance of its Biologics License Application for DMB-3115, reflects its dedication to quality and compliance. (intaspharma.com) As global regulatory requirements continue to evolve, Intas's focus on quality assurance and compliance positions it favorably in the competitive pharmaceutical export market.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Product Matching: Mitoxantrone shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
2.Supplier Identification: Intas Pharmaceuticals Limited matched across shipments using name normalization, accounting for company name formatting variations.
3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
4.Verified Records: This page is backed by 13 individual customs records matching Intas Pharmaceuticals Limited exporting Mitoxantrone, covering 10 formulations to 4 countries via 6 buyers.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

Global Coverage

Exports to 35+ countries, 56+ buyers

Expert-Reviewed

Analyzed by pharmaceutical trade specialists

Mitoxantrone

Mitoxantrone

Intas Pharmaceuticals Limited — Mitoxantrone Exporter Profile

Intas Pharmaceuticals Limited — Mitoxantrone Export Profile: Buyers & Destinations

Where Does Intas Pharmaceuticals Limited Export Mitoxantrone?

Who Are the Top Buyers of Mitoxantrone from Intas Pharmaceuticals Limited?

What Is India's Total Mitoxantrone Export Value and How Much Does Intas Pharmaceuticals Limited Contribute?

What Is the Average Shipment Value for Intas Pharmaceuticals Limited's Mitoxantrone Exports?

How Does Intas Pharmaceuticals Limited Compare to Other Indian Mitoxantrone Exporters?

What Mitoxantrone Formulations Does Intas Pharmaceuticals Limited Export?

Regulatory Requirements: Exporting Mitoxantrone to Key Markets

Mexico — COFEPRIS

How Does Intas Pharmaceuticals Limited Compare to Nearest Mitoxantrone Exporters?

Which Indian Ports Ship Mitoxantrone Exports?

Geopolitical & Trade Policy Impact on Intas Pharmaceuticals Limited's Mitoxantrone Exports

Intas Pharmaceuticals Limited — Regulatory Compliance & Quality Standards

About Intas Pharmaceuticals Limited

Market Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Get Mitoxantrone Export Data from Intas Pharmaceuticals Limited

Mitoxantrone Stats

Company Overview

Top Products by Intas Pharmaceuticals Limited

Related Analysis

Need Detailed Export Data?

Data Source